



PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

*In re* Application of: ) ) GAU: 1642  
Schneck and O'Herrin ) ) Examiner: Christopher H. Yaen  
Serial No.: 09/642,660 ) ) Docket No. 001107.00042  
Filed: August 22, 2000 ) )

For: **CELL COMPOSITIONS COMPRISING MOLECULAR COMPLEXES  
THAT MODIFY IMMUNE RESPONSES**

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

U.S. Patent and Trademark Office  
Customer Service Window  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314


Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, enclosed is a PTO Form-1449 listing documents for consideration by the Examiner during the prosecution of the subject application.

Please charge our Deposit Account No. 19-0733 in the amount of \$180.00 under 37 C.F.R. § 1.17(p) for the filing fee.

Respectfully submitted,

Dated: July 20, 2006

By:   
Lisa M. Hemmendinger  
Registration No. 42,653

Customer No. 22907

07/24/2006 HAL111 0000054 190733 09642660  
01 FC:1806 180.00 DA

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	09/642,660
Filing Date	August 22, 2000
First Named Inventor	Schneck
Group Art Unit	1643
Examiner Name	Christopher H. Yaen

Attorney Docket Number

001107.00042

## OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Deeths et al., "B7-1-Dependent co-stimulation results in qualitatively and quantitatively different responses by CD4 <sup>+</sup> and CD8 <sup>+</sup> T cells", European Journal of Immunology, Vol. 27, No. 3, 1997, pp 598-608.	
		OERTLI et al., "Artificial antigen-presenting cells engineered by recombinant vaccinia viruses expressing antigen, MHC class II, and costimulatory molecules elicit proliferation of CD4+lymphocytes invitro", Clinical and Experimental Immunology, Vol. 110, No. 1, October 1997, pp 144-149.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.